NCLEX-RN · Pharmacological and Parenteral Therapies · 8 min read
Insulin and Oral Diabetes Medications
- Differentiate the pharmacokinetics, administration guidelines, and safety considerations for rapid, short, intermediate, and long-acting insulins.
- Recognize acute glycemic emergencies, their physiological triggers, and appropriate rescue interventions.
- Evaluate indications, contraindications, and nursing considerations for non-insulin oral and injectable antidiabetic medications.
Insulin Formulations, Administration Techniques, and Storage
Insulin therapy replaces or supplements endogenous insulin to maintain glycemic stability. Rapid-acting insulins include lispro, aspart, and glulisine. These medications generally begin working within 10 to 30 minutes and reach their peak action about 30 minutes to 3 hours after administration, depending on the specific product. Because of this rapid activity, a meal should always be available before administration. Nurses generally administer rapid-acting insulin immediately before eating to reduce the risk of hypoglycemia. An everyday comparison is ordering food at a diner counter: you do not take the medication until the tray is directly in front of you. Regular insulin is a short-acting formulation with an onset of 30 to 60 minutes and a peak around 2 to 4 hours. Regular insulin is commonly used intravenously, although some rapid-acting insulin formulations can also be administered intravenously under appropriate protocols.
Intermediate-acting NPH and long-acting insulins provide basal coverage, but NPH has a pronounced peak and does not provide the relatively steady action of long-acting insulins. NPH is an intermediate-acting insulin that appears cloudy and requires gentle rolling between the palms before administration to ensure uniform dispersion. It has an onset of 1 to 2 hours, a peak of 4 to 12 hours, and a duration of 14 to 24 hours. In contrast, long-acting insulins include glargine, detemir, and degludec. Insulin glargine has no pronounced peak and provides steady basal insulin action for about 24 hours with U-100 formulations and even longer with U-300 formulations. A critical safety rule governs long-acting insulins: they must never be mixed in the same syringe with any other insulin formulation.
When preparing a combined dose of intermediate and short-acting insulins in one syringe, strict adherence to technique prevents cross-contamination. When preparing a mixed dose of NPH and regular insulin, air is injected into NPH first, air into regular second, regular insulin is drawn up first, and NPH is drawn up last. When administering subcutaneous injections, rotating injection sites within the same anatomical region helps prevent lipohypertrophy while supporting consistent absorption. Think of this like rotating where you set a heavy lawn chair across the same patch of grass so one spot does not become damaged. Proper storage is equally essential: unopened insulin should generally be refrigerated. Storage conditions and beyond-use periods for opened products vary, so nurses must follow the specific product labeling rather than assuming an arbitrary 28-day limit.
Continuous subcutaneous insulin infusion pumps offer an automated approach to basal-bolus therapy. These battery-powered pumps deliver a continuous basal rate of rapid-acting insulin throughout the day and night alongside client-directed pre-meal boluses. Safe pump management requires diligent site care to prevent delivery failures and tissue irritation. Standard insulin pump infusion sets are generally changed every 2 to 3 days, whereas extended-wear sets should be changed according to their specific product instructions.
| Insulin Class | Generic Examples | Onset | Peak Window | Duration and Key Administration Rules |
|---|---|---|---|---|
| Rapid-Acting | Lispro, aspart, glulisine | 10 to 30 minutes | 30 minutes to 3 hours | Administer immediately before eating with meal available; some formulations may be used IV under protocols |
| Short-Acting | Regular insulin | 30 to 60 minutes | 2 to 4 hours | Commonly used intravenously; drawn up before NPH when preparing mixed doses |
| Intermediate-Acting | NPH | 1 to 2 hours | 4 to 12 hours | Duration of 14 to 24 hours; cloudy suspension requiring gentle rolling; drawn up last in mixtures |
| Long-Acting | Glargine, detemir, degludec | Basal coverage | No pronounced peak (glargine) | Duration of about 24 hours (U-100 glargine) or longer (U-300); never mix in a syringe with other insulins |
Common mistakes
- Assuming all opened insulin vials must be discarded precisely after 28 days, rather than following the specific manufacturer product labeling.
- Treating acute hypoglycemia with sucrose or table sugar in a client taking an alpha-glucosidase inhibitor like acarbose, instead of using pure oral glucose tablets.
- Withholding basal insulin entirely during acute illness when a client is not eating, instead of following sick-day rules, continuing basal insulin, and checking glucose every 2 to 4 hours.
- Assuming that a reported allergy to sulfonamide antibiotics automatically precludes the administration of sulfonylureas like glipizide or glimepiride without assessing the prior reaction.
Key points
- Rapid-acting insulins (lispro, aspart, glulisine) require meals to be immediately available, while long-acting insulins (glargine, detemir, degludec) provide basal coverage and must never be mixed with other insulins.
- When mixing NPH and regular insulin in one syringe, inject air into NPH first, air into regular second, draw up regular first, and draw up NPH last.
- Treat hypoglycemia in conscious clients using 15 grams of fast-acting carbohydrate with a 15-minute recheck; use IM/SubQ glucagon or IV dextrose (D10W or D50W) for unconscious clients.
- Metformin reduces hepatic glucose production without stimulating insulin secretion, carries a risk of lactic acidosis, is contraindicated with an eGFR below 30 mL/min/1.73 m², and is held around iodinated contrast procedures based on renal function and procedure type.
- Secretagogues such as sulfonylureas and meglitinides increase insulin release and hypoglycemia risk; meglitinide doses must be omitted if a meal is skipped.
- Thiazolidinediones can worsen heart failure and cause fluid retention, whereas SGLT2 inhibitors cause osmotic diuresis, genital mycotic infections, and risk of euglycemic DKA.
Practice this section
Explained NCLEX Pharmacological and Parenteral Therapies questions, no account needed. NCLEX Pharmacological and Parenteral Therapies practice test
The full lesson continues with 3 more sections with exam tips, audio in English and Spanish, 5 Check yourself questions and 20 flashcards.
- 1 month
$58.99$29.49 - 3 months
$173.99$86.99 - Lifetime
$350.99$175.49
One payment, no subscription.
See NCLEX plansAlready a member? Log in
Sample lesson: Medication Safety and the Rights of Administration25 practice questions on this exam
Each NCLEX practice test has 25 original questions with the answers explained. No account needed.
Open the NCLEX practice testsOriginal lesson written for NCLEX-RN practice · updated October 31, 2026. Exam names are trademarks of their owners; tests.global is not affiliated with them.